A
Atsuhiro Sugidachi
Researcher at Daiichi Sankyo
Publications - 90
Citations - 2889
Atsuhiro Sugidachi is an academic researcher from Daiichi Sankyo. The author has contributed to research in topics: Prasugrel & Thienopyridine. The author has an hindex of 24, co-authored 89 publications receiving 2774 citations. Previous affiliations of Atsuhiro Sugidachi include University of Massachusetts Medical School & Ube Industries.
Papers
More filters
Journal ArticleDOI
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
Lars Wallentin,Christoph Varenhorst,Stefan James,David Erlinge,Oscar Ö. Braun,Joseph A. Jakubowski,Atsuhiro Sugidachi,Kenneth J. Winters,Agneta Siegbahn +8 more
TL;DR: In aspirin-treated subjects with coronary artery disease, prasugrel 60/10 mg provides faster onset and greater inhibition of P2Y(12) receptor-mediated platelet aggregation than clopidogrel 600/75 mg, because of greater and more efficient generation of the active metabolite.
Journal ArticleDOI
Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.
TL;DR: Studies conducted to date indicate that CS-747 is a highly effective antiplatelet and antithrombotic agent and is anticipated to be effective in the treatment of atherothrombosis and other ischemic vascular diseases.
Journal ArticleDOI
The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties
TL;DR: In vivo pharmacological profiles of CS‐747 show that it is an orally active and a potent antiplatelet and antithrombotic agent with a rapid onset and long duration of action, and warrants clinical evaluations of the agent.
Journal ArticleDOI
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.
David Erlinge,Christoph Varenhorst,Oscar Ö. Braun,Stefan James,Kenneth J. Winters,Joseph A. Jakubowski,John T. Brandt,Atsuhiro Sugidachi,Agneta Siegbahn,Lars Wallentin +9 more
TL;DR: The mechanism of incomplete platelet inhibition in clopidogrel poor-responder groups and in diabetic patients is lower plasma levels of its AM and not differences in platelet P2Y(12) receptor function.
Journal ArticleDOI
The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite.
Atsuhiro Sugidachi,T. Ogawa,A. Kurihara,K. Hagihara,Joseph A. Jakubowski,Masami Hashimoto,Y. Niitsu,F. Asai +7 more
TL;DR: The greater in vivo antiplatelet potency of prasug Rel reflects more efficient in vivo generation of its AM, which demonstrates similar in vitro activity to clopidogrel AM.